1-14 of 14
Ken Ogasawara
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies

Fabian Mueller, Krish Patel, Ran Reshef, Mohamad Cherry, Richard Nash, Ernesto Ayala, Jingmei Hsu, Jacques Azzi, Peter Vandenberghe, Roch Houot, Bastian von Tresckow, Giuseppina Stifano, Ashley Koegel, Susana Falcon, Burhan Chaudhry, Lisa Kelly, Jerill Thorpe, Alyse Frisbee, Sam Charab, Sharmila Das, Thomas Ly, Ken Ogasawara, Paolo Caimi
Journal: Blood
Blood (2024) 144 (Supplement 1): 2088.
https://doi.org/10.1182/blood-2024-194525
Published: 2024
Journal Articles

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon E. Arnason, Manali Kamdar, David G. Maloney, Mazyar Shadman, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Juliana E. Hidalgo-López, Jing Wang, Ken Ogasawara, Ashvin Singh, Tanya Siddiqi
Journal: Blood
Blood (2024) 144 (Supplement 1): 3125.
https://doi.org/10.1182/blood-2024-200204
Published: 2024
Journal Articles

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Clinical Trials & Observations
Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison Sehgal, Scott R. Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi
Journal: Blood
Blood (2024) 143 (5): 404–416.
https://doi.org/10.1182/blood.2023020854
Published: 2024
Includes: Supplemental data
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

Maria Lia Palomba, Tanya Siddiqi, Leo I. Gordon, Manali Kamdar, Matthew A Lunning, Alexandre V Hirayama, Jeremy S. Abramson, Jon E. Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott R. Solomon, Ana Kostic, Ashvin Singh, Ricardo Espinola, Lily Peng, Ken Ogasawara, Amy Chattin, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 3505.
https://doi.org/10.1182/blood-2023-178109
Published: 2023
Journal Articles

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Alison R Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard Hildebrandt, John E. Godwin, Patrick M. Reagan, Nina Wagner-Johnston, James Essell, Rajneesh Nath, Scott R. Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel K. Gupta, Victor A Chow, Brenda Yuan, Zhi Yang, Ken Ogasawara, Jerill Thorpe, Leo I. Gordon
Journal: Blood
Blood (2023) 142 (Supplement 1): 105.
https://doi.org/10.1182/blood-2023-180952
Published: 2023
Journal Articles

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Clinical Trials & Observations
Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar
Journal: Blood
Blood (2023) 141 (14): 1675–1684.
https://doi.org/10.1182/blood.2022018730
Published: 2023
Includes: Supplemental data
Journal Articles

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Clinical Trials & Observations
Tanya Siddiqi, Jacob D. Soumerai, Kathleen A. Dorritie, Deborah M. Stephens, Peter A. Riedell, Jon Arnason, Thomas J. Kipps, Heidi H. Gillenwater, Lucy Gong, Lin Yang, Ken Ogasawara, Jerill Thorpe, William G. Wierda
Journal: Blood
Blood (2022) 139 (12): 1794–1806.
https://doi.org/10.1182/blood.2021011895
Published: 2022
Includes: Supplemental data
Journal Articles

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Manali Kamdar, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim G.N.J. Mutsaers, Francisco J. Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, David G. Maloney, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Lara Stepan, Ken Ogasawara, Timothy Mack, Jeremy S. Abramson
Journal: Blood
Blood (2021) 138 (Supplement 1): 91.
https://doi.org/10.1182/blood-2021-147913
Published: 2021
Journal Articles

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon E. Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Ana Kostic, Yeonhee Kim, Ken Ogasawara, Christine Dehner, Tanya Siddiqi
Journal: Blood
Blood (2021) 138 (Supplement 1): 2840.
https://doi.org/10.1182/blood-2021-148948
Published: 2021
Journal Articles

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

John E. Godwin, Bassam Mattar, Michael Maris, Carlos Bachier, Don Stevens, Daanish Hoda, Juan C. Varela, Mohamad Cherry, Suzanne Fanning, James Essell, Habte Yimer, Jay Courtright, Jeff P. Sharman, Ricardo Espinola, Connor Mailley, Ariel Avilion, Ken Ogasawara, San-San Ou, Paul Shaughnessy
Journal: Blood
Blood (2021) 138 (Supplement 1): 1762.
https://doi.org/10.1182/blood-2021-148792
Published: 2021
Journal Articles

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

Maria Lia Palomba, MD, Leo I. Gordon, MD, Tanya Siddiqi, MD, Jeremy S. Abramson, MD, Manali Kamdar, MD, Matthew A. Lunning, DO, FACP, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Jon E. Arnason, MD, Nilanjan Ghosh, MD PhD, Amitkumar Mehta, MD, Scott R. Solomon, MD, Thalia Farazi, MD PhD, Jacob Garcia, MD, Christine Dehner, BSc, Ken Ogasawara, PhD MPH, Jie Gao, PhD, Michael Wang, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-136158
Published: 2020
Journal Articles

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

William G. Wierda, MD PhD, Kathleen A. Dorritie, MD, Javier Munoz, MD, Deborah M. Stephens, DO, Scott R. Solomon, MD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Lin Yang, PhD, Ken Ogasawara, PhD MPH, Jerill Thorpe, BS, Tanya Siddiqi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-140622
Published: 2020
Journal Articles

Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Lin Yang, PhD, Ken Ogasawara, PhD MPH, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-140491
Published: 2020
Journal Articles

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Carlos R. Bachier, MD, Maria Lia Palomba, MD, Jeremy S. Abramson, MD MMSc, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, John Godwin, Gerhard C. Hildebrandt, MD, Tanya Siddiqi, MD, Don Stevens, MD, Thalia Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, PhD, James Lymp, PhD, Tennille Thelen, Ken Ogasawara, David G. Maloney, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2868.
https://doi.org/10.1182/blood-2019-127566
Published: 2019